30-04-2025
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
REDWOOD CITY, Calif. & BOSTON, April 30, 2025--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York.
Details of the event are as follows:Date: Wednesday, May 7, 2025Time: 1:30 p.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio's website at An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at
View source version on
Contacts
Adicet Bio, Inc.
Investor and Media Contacts
Investors: Anne Bowdidgeabowdidge@
Penelope BelnapPrecision
Media: Kerry Beth Dalykbdaly@
